Drug Approval | June 15, 2022
Eli Lilly gets FDA approval for alopecia drug
Alopecia areata usually presents as a few small bald patches in the head
Alopecia areata usually presents as a few small bald patches in the head
First and only FDA-approved device of its kind demonstrates consistently high rates of target limb salvage and freedom from clinically-driven target lesion revascularization
Acceptance based on results from the phase 3 KEYNOTE-091 trial
Marinus has broadened inclusion criteria in the RAISE trial to allow for enrollment of patients previously treated with IV anesthesia.
Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood
TP-3654 is currently being evaluated in a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with intermediate or high-risk primary or secondary myelofibrosis.
TLANDO was approved by the U.S. Food and Drug Administration (FDA) on March 28, 2022.
Dr. Bernstein will tap into her decades of leadership and strategy experience as she transitions into this new role at APhA
Radicava ORS was approved by the U.S. Food and Drug Administration (FDA) on May 12, 2022
Dupixent would be the first and only medicine specifically indicated to treat prurigo nodularis in the U.S., if approved
Subscribe To Our Newsletter & Stay Updated
